The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac. ##STR00001##

The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R.sup.1, R.sup.2 and R.sup.3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I):

##STR00001##

and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R.sup.1, R.sup.2 and R.sup.3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

The disclosure provides a method for preparing drug toxin PNU-159682 (morpholinyl anthracycline derivative) for antibody-conjugated drugs and intermediates involved in the preparation method. The preparation method of the present disclosure improves the stability, practicability and scalability of the process by introducing protecting groups and changing to reagents that are capable to amplify; the preparation method of the present disclosure minimizes the risk and operational difficulty during scale-up production; production and operation is simple and convenient.

The disclosure provides a method for preparing drug toxin PNU-159682 (morpholinyl anthracycline derivative) for antibody-conjugated drugs and intermediates involved in the preparation method. The preparation method of the present disclosure improves the stability, practicability and scalability of the process by introducing protecting groups and changing to reagents that are capable to amplify; the preparation method of the present disclosure minimizes the risk and operational difficulty during scale-up production; production and operation is simple and convenient.

A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

A compound of the general formula (1). The compound of formula (1) is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Also, a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

The present invention relates to compounds of formula (I), ##STR00001##
wherein R.sup.1, R.sup.2 and R.sup.3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

The present invention relates to compounds of formula (I), ##STR00001##
wherein R.sup.1, R.sup.2 and R.sup.3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.

The present disclosure relates to compounds and compositions containing 5′-phosphoramidite nucleoside monomers of formulae (I) and (II), and methods of making and use, wherein the substituents are as defined in the appended claims. ##STR00001##